Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02252653 · ClinicalTrials.gov registry record
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
A clinical trial of Familial Amyloidotic Cardiomyopathy (FAC), sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- 1,010
- Enrollment target
- 20
- Study locations
NCT02252653 is a study of Familial Amyloidotic Cardiomyopathy (FAC) that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 1,010 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT02252653, a study of Familial Amyloidotic Cardiomyopathy (FAC), has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- 1,010 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis
Conditions Studied
Study Locations (20)
California
- Clinical Trial Site - Bakersfield
- Clinical Trial Site - La Mesa
- Clinical Trial Site - Los Angeles
- Clinical Trial Site - Los Angeles
- Clinical Trial Site - San Francisco
- Clinical Trial Site - Torrance
Georgia
- Clinical Trial Site - Athens
- Clinical Trial Site - Atlanta
- Clinical Trial Site - Atlanta
- Clinical Trial Site - Macon
District of Columbia
- Clinical Trial Site - Washington D.C.
- Clinical Trial Site - Washington D.C.
- Clinical Trial Site - Washington D.C.
Illinois
- Clinical Trial Site - Chicago
- Clinical Trial Site - Chicago
- Clinical Trial Site - Chicago
Arkansas
- Clinical Trial Site - Little Rock
Colorado
- Clinical Trial Site - Aurora
Florida
- Clinical Trial Site - Tampa
Indiana
- Clinical Trial Site - Merrillville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,010 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02252653
The ClinicalTrials.gov registry entry for NCT02252653 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,010 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Familial Amyloidotic Cardiomyopathy (FAC) appearing as the primary indexed condition, and to 0 interventions.
NCT02252653 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Georgia, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02252653 about?
NCT02252653 is a clinical study titled "DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis". The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis
What is the current status of trial NCT02252653?
This trial is currently completed. The enrollment target is 1,010 participants. The study started on 2014-06. Estimated completion is 2016-03.
What conditions does trial NCT02252653 study?
This clinical trial studies the following conditions: Familial Amyloidotic Cardiomyopathy (FAC).
Who is sponsoring clinical trial NCT02252653?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02252653 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.